Benzinga | Oct 14, 2020 07:04AM EDT

Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program

Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it will host an educational webinar on Thursday, October 22, at 1:00 p.m. ET to review multiple aspects of Angelman syndrome, including its biological mechanism, and the Company's OV101 (gaboxadol) development program. The webinar will feature external experts discussing topics that includes the role of tonic inhibition, treatment practice in Angelman syndrome, measurement scales and what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome.

Webinar Agenda & Presenters:

* Welcome and Introduction Jeremy M. Levin, DPhil, MB BChir -- Chairman and Chief Executive Officer at Ovid Therapeutics

* Tonic Inhibition, Angelman Syndrome, and OV101 Matthew During, M.D., DsC, FACP, FRACP -- Founder of Ovid Therapeutics

* Treating a Patient with Angelman Syndrome Christopher Keary, M.D. -- Child, Adolescent and Adult Psychiatrist, Massachusetts General Hospital for Children

* The Importance of Clinical Global Impressions of Improvement (CGI-I) Judith Jaeger, Ph.D., MPA -- President & Principal Scientist, CognitionMetrics, LLC

* OV101 in Angelman Syndrome, Clinical Results and What to Expect from NEPTUNE Amit Rakhit, M.D., MBA -- President and Chief Medical Officer at Ovid Therapeutics

* Compelling Market Opportunity Jason Tardio -- Chief Commercial Officer at Ovid Therapeutics

Webinar Registration & Information

Date: Thursday, October 22

Time: 1:00 p.m. ET